Search results for " YY1"

showing 4 items of 4 documents

FKBP51 Affects TNF-Related Apoptosis Inducing Ligand Response in Melanoma

2021

Melanoma is one of the most immunogenic tumors and has the highest potential to elicit specific adaptive antitumor immune responses. Immune cells induce apoptosis of cancer cells either by soluble factors or by triggering cell-death pathways. Melanoma cells exploit multiple mechanisms to escape immune system tumoricidal control. FKBP51 is a relevant pro-oncogenic factor of melanoma cells supporting NF-κB-mediated resistance and cancer stemness/invasion epigenetic programs. Herein, we show that FKBP51-silencing increases TNF-related apoptosis-inducing ligand (TRAIL)-R2 (DR5) expression and sensitizes melanoma cells to TRAIL-induced apoptosis. Consistent with the general increase in histone d…

Programmed cell deathQH301-705.5ChemistryYY1MelanomaRepressorTRAILCell Biologymedicine.diseaseYY1TRAIL melanoma cell death FKBP51 YY1Cell and Developmental Biologycell deathFKBP51Immune systemApoptosisCancer cellmelanomaCancer researchmedicineBiology (General)Transcription factorOriginal ResearchDevelopmental BiologyFrontiers in Cell and Developmental Biology
researchProduct

Yin Yang 1 and raf-1 Kinase Inhibitory Protein Status in Hepatocellular carcinoma: Future Perspectives

2010

We focus on to the role of the transcription factors NF-κB and Yin Yang 1 (YY1) and of Raf-1 kinase inhibitory protein (RKIP) in hepatocellular carcinoma (HCC). YY1, whose expression is enhanced by NF-κB, favors tumorigenesis. RKIP inhibits the oncogenic activities of MAPK and NF-κB pathways and promotes drug-induced apoptosis. Mutual influences between YY1 and RKIP may exist and there is separate evidence that relevant increases in YY1 and reductions in RKIP occur in HCC. In a recent study on clinical HCC, we found that, indeed, the ratio of YY1 to RKIP mRNA and protein expression is very frequently profoundly inverted in tumors compared with adjacent tissues. Hyperactivation of YY1 in tum…

SorafenibSettore MED/12 - GastroenterologiaHepatocellular carcinoma Yin Yang 1 RKIP YY1AP NF-kB Sorafenibbusiness.industryInhibitory postsynaptic potentialmedicine.diseaseBiochemistryYIN-YANG-1Hepatocellular carcinomaRaf 1 kinaseSettore BIO/14 - FarmacologiaGeneticsmedicineCancer researchMolecular MedicinebusinessBiotechnologymedicine.drugForum on Immunopathological Diseases and Therapeutics
researchProduct

Commentary. Regulation of drug and immune resistance by YY1 in cancer.

2010

DrugYY1business.industrymedia_common.quotation_subjectImmune resistanceCancermedicine.diseaseBiochemistryDrug resistance YY1 NF-kB artesunateImmunologyGeneticsmedicineSettore BIO/14 - FarmacologiaMolecular MedicinebusinessBiotechnologymedia_common
researchProduct

Hepatocellular Carcinoma: A Difficult Cancer to Treat

2021

Hepatocellular carcinoma (HCC) is a very peculiar cancer because it presents several molecular alterations linked to the activation of survival and antiapoptotic signal pathways that are protein in form and not easily targetable by even the newest targeted therapies. In addition, it is almost always a consequence of liver cirrhosis, a serious disease condition in which several drugs are often not tolerated. This is why the study of HCC was such a challenge for Professor Natale D'Alessandro, to whom this work is dedicated, during the latter years of his career. The aim of this review is to summarize studies on different molecules involved in the development, progression, and chemoresistance …

Liver CirrhosisCancer ResearchCarcinoma HepatocellularCirrhosisDruggabilityDrug resistanceNuclear factor κbDiseaseYY1medicineHumansInterleukin 6IL-6drug resistancebiologybusiness.industryLiver NeoplasmsCancerhepatocellular carcinomamedicine.diseasedigestive system diseasescyclooxygenasesHepatocellular carcinomaNF-?Bbiology.proteinCancer researchEpatocarcinoma ciclossigenasi NF-kB IL-6 farmacoresistenza YY1businessSignal TransductionCritical Reviews™ in Oncogenesis
researchProduct